|
|
|
|
|
Atomoxetine
drug data and news
Atomoxetine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Atomoxetine | ||
| Brand Names/Synonyms | Atomoxetine; Strattera; Tomoxetina [Spanish]; Tomoxetine; Tomoxetine [Inn]; Tomoxetinum [Latin] | ||
| Indication | For the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Atomoxetine is an amphetamine used to treat ADD/ADHD in children and adults. Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. It increases motor activity and mental alertness, and reduces drowsiness and a sense of fatigue, decreasing motor restlessness and improves one's ability to focus. Peripheral actions include elevation of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action. There is neither specific evidence which clearly establishes the mechanism whereby amphetamine produces mental and behavioral effects in children, nor conclusive evidence regarding how these effects relate to the condition of the central nervous system. Atomoxetine activates the brain stem arousal system and cortex to produce its stimulant effect. | ||
| Mechanism Of Action | Amphetamines release stores of norepinephrine and dopamine from nerve endings by converting the respective molecular transporters into open channels. Amphetamines also releases stores of serotonin from synaptic vesicles. Like methylphenidate (Ritalin) amphetamines also prevent the monoamine transporters for dopamine and norepinephrine from recycling them (called reuptake inhibition) which leads to increased amounts of dopamine and norepinephrine in synaptic clefts. These combined effects rapidly increases the concentrations of the respective neurotransmitters in the synaptic cleft, which promotes nerve impulse transmission in neurons that have those receptors. | ||
| Atomoxetine News (When available) |
Treating ADD With Medication 06 Mar 2006 Monoaminergic Treatment of Schizophrenia Feb 27, 2006 Researchrs may have found alternative to hyperactivity drug Feb 15, 2006 Can you find concentration in a bottle Feb 18, 2006 FDA eyes ADHD drug heart attack risks Feb 1, 2006 Attention-Deficit/Hyperactivity Disorder and Substance Use ... Jan 23, 2006 FDA eyes ADHD drug heart attack risks Feb 1, 2006 Lilly Reports Q4 EPS of $.64, or $.80 Excluding Charges; 2005 EPS ... Jan 26, 2006 Lilly Reports Q4 EPS of $.64, or $.80 Excluding Charges; 2005 EPS ... Jan 26, 2006 Clinical Guidelines for Psychiatrists for the Use of ... Jan 23, 2006 Acute Treatment with Atomoxetine Equally Effective in Children and ... Nov 14, 2005 Atomoxetine (Strattera) Improves Executive Function in ADHD ... Nov 10, 2005 Medications Used to Treat ADHD Nov 30, 2005 ADHD and Comorbid Medical and Psychiatric Disorders Dec 1, 2005 Understanding is key to helping ADHD child Dec 9, 2005 Reader looks to control drinking to save marraige Dec 5, 2005 Are safety labeling and safety warnings enough? Nov 23, 2005 ADDERALL XR(R) Significantly Improves Driving Performance and ... Nov 8, 2005 ADDERALL XR(R) Significantly Improves Driving Performance and ... Nov 8, 2005 FDA Issues Public Health Advisory on Strattera (Atomoxetine) for ... Sep 29, 2005 FDA MedWatch - Strattera (atomoxetine) - Increased risk of suicid ... Sep 29, 2005 ADHD, increased risk of suicidal thinking for Strattera Oct 8, 2005 Attention please…..we have another FDA Public Health advisory Oct 5, 2005 FDA issues advisory on ADHD drug, Strattera Sep 30, 2005 ADHD, Strattera linked to increased risk of suicidal thinking Oct 2, 2005 Lilly to add suicide warning to drug Strattera Sep 29, 2005 FDA Warns About ADHD Drug Strattera Sep 29, 2005 Across the nation Sep 30, 2005 Lilly to Include Warning about Suicidal Thoughts on Strattera ... Sep 29, 2005 FDA Advisories on taking Paxil During Pregnancy Oct 3, 2005 Researchers Find Few Comparisons of Most ADHD Drugs Sep 27, 2005 Desperate children... Sep 10, 2005 Getting an Edge — Use of Stimulants and Antidepressants in ... Sep 16, 2005 The Hard Work of Growing Up With ADHD Aug 31, 2005 The Molecular Genetics of ADHD: A View From the IMAGE Project Aug 30, 2005 Helping kids with ADHD Aug 17, 2005 Hyperactivity drug hardly affects kids' growth Jul 28, 2005 ADHD: Eli Lilly's Strattera set to drive global market Jul 7, 2005 Concerta Label Change Likely but Generics Pose Greater Threat Jul 6, 2005 | ||
| Dosage Forms | CAPSULE | ||
| Drug_Category | Antidepressants; Central Nervous System Agents; ATC:N06BA09 | ||
| Absorption | Not Available | ||
| Interactions |
-->Interactions for Atomoxetine: Drug-Drug Interactions Albuterol ¾ STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure. CYP2D6 inhibitors ¾ Atomoxetine is primarily metabolized by the CYP2D6 pathway to 4-hydroxyatomoxetine. In EMs, selective inhibitors of CYP2D6 increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in PMs. Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine (see DOSAGE AND ADMINISTRATION). In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone. In vitro studies suggest that coadministration of cytochrome P450 inhibitors to PMs will not increase the plasma concentrations of atomoxetine. Monoamine oxidase inhibitors ¾ See CONTRAINDICATIONS. Pressor agents ¾ Because of possible effects on blood pressure, STRATTERA should be used cautiously with pressor agents. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | N-methyl-3-(2-methylphenoxy)-3-phenyl-propan-1-amine | ||
| Chemical Formula | C17H21NO | ||
| Molecular Weight | 255.355 g/mol | ||
| Smiles String | CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2 | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 4.656 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 5 hours | ||
| Protein Binding [%] | 40% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Atomoxetine.html http://www.rxlist.com/cgi/generic3/strattera.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00614 | ||
| CAS Registry Number | 82248-59-7 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | SID:214424 | ||
| PharmGKB ID | PA134688071 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2262800 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |